Nefúði, Dreifa (Azelastine Hydrochloride, Fluticasone Propionate)

Azelastine hydrochloride acts as a selective H1‑histamine receptor antagonist. By blocking these receptors in the nasal mucosa, it prevents histamine‑mediated vasodilation and sensory nerve activation, thereby reducing itching, sneezing, and watery discharge.

The prescribed dose of Nefúði, Dreifa is determined by the treating healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the specific instructions provided by their prescriber.

Safety in pregnancy and lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nefúði, Dreifa combines an antihistamine (azelastine) with a corticosteroid (fluticasone) in a single spray, offering both rapid symptom relief and anti‑inflammatory action. Single‑agent sprays contain either an antihistamine or a steroid, which may require separate products to achieve comparable efficacy.

Store the nasal spray at room temperature, below 25 °C, in the original packaging. Keep it away from moisture and direct sunlight to maintain product stability and potency.

The spray is administered intranasally. The patient tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks include nasal septal perforation, severe allergic reactions such as anaphylaxis, and potential adrenal suppression with prolonged high‑dose use. Patients should seek immediate medical attention if they experience unusual bleeding, vision changes, or signs of a severe allergic response.

Individuals with known hypersensitivity to azelastine, fluticasone, or any excipients in the formulation should avoid using this product. It is also contraindicated in patients who require other intranasal corticosteroids concurrently without medical supervision.